BeOne Medicines Highlights Global Footprint With Latest Form 10-Q Filing

BeOne Medicines Ltd ( (HK:6160) ) has shared an announcement.

BeOne Medicines Ltd. has released its quarterly report on Form 10-Q for the period ended March 31, 2026, which was filed with the U.S. Securities and Exchange Commission and simultaneously announced in Hong Kong under the exchange’s overseas regulatory disclosure rules. The filing confirms the company’s compliance with ongoing U.S. reporting requirements, highlights its status as a large accelerated filer and non-shell company, and underscores its increasingly global shareholder base via listings in the U.S., Hong Kong, and Shanghai.

The announcement also reiterates the structure of BeOne’s capital, noting 1,445,262,342 ordinary shares outstanding as of April 30, 2026, including those represented by American Depositary Shares and RMB shares in mainland China. Governance details were provided through an updated board composition led by Chairman and Executive Director John V. Oyler, signaling continued emphasis on regulatory transparency and corporate oversight for investors across multiple markets.

The most recent analyst rating on (HK:6160) stock is a Buy with a HK$290.00 price target. To see the full list of analyst forecasts on BeOne Medicines Ltd stock, see the HK:6160 Stock Forecast page.

More about BeOne Medicines Ltd

BeOne Medicines Ltd. is a Switzerland-incorporated biopharmaceutical company whose ordinary shares trade in Hong Kong under stock code 06160 and via American Depositary Shares on the Nasdaq Global Select Market under the symbol ONC. The company also has RMB-denominated ordinary shares listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange for permitted investors in China, reflecting a multi-market capital markets strategy.

Average Trading Volume: 3,721,116

Technical Sentiment Signal: Buy

Current Market Cap: HK$263.1B

Find detailed analytics on 6160 stock on TipRanks’ Stock Analysis page.